Long-term persistence of acquired resistance to 5-fluorouracil in the colon cancer cell line SW620

Experimental Cell Research

Volumn 316, Issue 19, 2010, Pages 3172-3181

  Tentes, I K ^a   Schmidt, W M ^b   Krupitza, G ^b   Steger, G G ^b   Mikulits, W ^b   Kortsaris, A ^a   Mader, R M ^b  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

5 fluorouracil; Colon cancer; Epigenetics; Stem cell; SW620, chemoresistance; Transdifferentiation

Indexed keywords

BETA CATENIN; CD133 ANTIGEN; FLUOROURACIL; HERMES ANTIGEN; UVOMORULIN; AZACITIDINE; CADHERIN; CULTURE MEDIUM; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ARTICLE; CANCER CELL CULTURE; CANCER MODEL; CELL DIVISION; COLON CANCER; DRUG STABILITY; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; IN VITRO STUDY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; CELL ADHESION; CELL DEATH; CELL PROLIFERATION; COLONIC NEOPLASMS; CULTURE MEDIUM; DNA METHYLATION; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIUM; GENETIC EPIGENESIS; HUMAN; IC50; KINETICS; MESODERM; METABOLISM; PATHOLOGY; PHARMACOLOGY; TIME; TUMOR CELL LINE;

ANTIGENS, CD; ANTIGENS, CD44; AZACITIDINE; BETA CATENIN; CADHERINS; CELL ADHESION; CELL DEATH; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CULTURE MEDIA, SERUM-FREE; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; EPITHELIUM; FLUOROURACIL; GLYCOPROTEINS; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MESODERM; PEPTIDES; TIME FACTORS;

EID: 77958101719     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.09.003     Document Type: Article

References (22)

1. Schmidt W.M., Kalipciyan M., Dornstauder E., Rizovski B., Steger G.G., Sedivy R., Mueller M.W., Mader R.M. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int. J. Cancer 2004, 112:200-212.
2. Feinberg A.P., Ohlsson R., Henikoff S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7:21-33.
3. Bredberg A., Bodmer W. Cytostatic drug treatment causes seeding of gene promoter methylation. Eur. J. Cancer 2007, 43:947-954.
4. Mader R.M., Sieder A.E., Braun J., Rizovski B., Kalipciyan M., Mueller M.W., Jakesz R., Rainer H., Steger G.G. Transcription and activity of 5-fluorouracil converting enzymes in fluoropyrimidine resistance in colon cancer in vitro. Biochem. Pharmacol. 1997, 54:1233-1242.
5. Varga A.E., Stourman N.V., Zheng Q., Safina A.F., Quan L., Li X., Sossey-Alaoui K., Bakin A.V. Silencing of the Tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-beta. Oncogene 2005, 24:5043-5052.
6. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., Molloy P.L., Paul C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 1992, 89:1827-1831.
7. Grusch M., Polgar D., Gfatter S., Leuhuber K., Huettenbrenner S., Leisser C., Fuhrmann G., Kassie F., Steinkellner H., Smid K., Peters G.J., Jayaram H.N., Klepal W., Szekeres T., Knasmuller S., Krupitza G. Maintenance of ATP favours apoptosis over necrosis triggered by benzamide riboside. Cell Death Differ. 2002, 9:169-178.
8. Huettenbrenner S., Maier S., Leisser C., Polgar D., Strasser S., Grusch M., Krupitza G. The evolution of cell death programs as prerequisites of multicellularity. Mutat. Res. 2003, 543:235-249.
9. Guo X., Goessl E., Jin G., Collie-Duguid E.S., Cassidy J., Wang W., O'Brien V. Cell cycle perturbation and acquired 5-fluorouracil chemoresistance. Anticancer Res. 2008, 28:9-14.
10. De Angelis P.M., Svendsrud D.H., Kravik K.L., Stokke T. Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol. Cancer 2006, 5:20.
11. Yoshiba S., Ito D., Nagumo T., Shirota T., Hatori M., Shintani S. Hypoxia induces resistance to 5-fluorouracil in oral cancer cells via G(1) phase cell cycle arrest. Oral Oncol. 2009, 45:109-115.
12. Morales C., Ribas M., Aiza G., Peinado M.A. Genetic determinants of methotrexate responsiveness and resistance in colon cancer cells. Oncogene 2005, 24:6842-6847.
13. Morales C., Garcia M.J., Ribas M., Miro R., Munoz M., Caldas C., Peinado M.A. Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol. Cancer Ther. 2009, 8:424-432.
14. Schmidt W.M., Sedivy R., Forstner B., Steger G.G., Zochbauer-Muller S., Mader R.M. Progressive up-regulation of genes encoding DNA methyltransferases in the colorectal adenoma-carcinoma sequence. Mol. Carcinog. 2007, 46:766-772.
15. Nyce J., Leonard S., Canupp D., Schulz S., Wong S. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc. Natl. Acad. Sci. USA 1993, 90:2960-2964.
16. El-Bahrawy M., Poulsom R., Rowan A.J., Tomlinson I.T., Alison M.R. Characterization of the E-cadherin/catenin complex in colorectal carcinoma cell lines. Int. J. Exp. Pathol. 2004, 85:65-74.
17. Davies M.L., Roberts G.T., Spiller D.G., Wakeman J.A. Density-dependent location and interactions of truncated APC and beta-catenin. Oncogene 2004, 23:1412-1419.
18. Arumungam T., Ramachandran V., Fournier K.F., Wang H., Marquis L., Abbruzzese J.L., Gallick G.E., Lodgson C.D., McConkey D.J., Choi W. Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 2009, 69:5820-5828.
19. Bates R.C., Edwards N.S., Burns G.F., Fisher D.E. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001, 61:5275-5283.
20. Dallas N.A., Xia L., Fan F., Gray M.J., Gaur P., van Buren G., Samuel S., Kim M.P., Lim S.J., Ellis L.M. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009, 69:1951-1957.
21. Sharma S.V., Lee D.Y., Li B., Quinlan M.P., Takahashi F., Maheswaran S., McDermott U., Azizian N., Zou L., Fischbach M.A., Wong K.K., Bradstetter K., Wittner B., Ramaswamy S., Classon M., Settleman J. A chromatin-mediated reversible drug-tolerant state in cancer subpopulations. Cell 2010, 141:69-80.
22. Suzuki M., Shinohara F., Nishimura K., Echigo S., Rikiishi H. Epigenetic regulation of chemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. Int. J. Oncol. 2007, 31:1449-1456.